Pharmacologic Treatment of Obesity

Halpern, Alfredo; Heymsfield, Steven B.; Van Gaal, Luc
January 2011
Journal of Obesity;2011, Vol. 2011, Special section p1
Academic Journal
The article provides information on the CB1 receptor antagonist Rimonabant which was introduced in the European mass market showing weight loss benefits. Following the emergence of significant side effects, including severe mood disorders, the drug was withdrawn from the market. Several lessons learned from the failure of the Rimonabant to achieve its clinical objectives are also discussed.


Related Articles

  • Options for treating obesity. Campbell, Ian // GP: General Practitioner;4/26/2002, p70 

    Focuses on the options for general practitioners in treating obesity. Effectiveness of anti-obesity drugs; Requirements for drug administration; Importance of setting realistic targets.

  • Long-Term Results of Drug Treatment for Obesity. SLAWSON, DAVID // American Family Physician;3/1/2014, Vol. 89 Issue 5, p389 

    The article presents answers to a question on whether weight loss medications are effective as long-term treatment for obesity.

  • 5 that work. Nachatelo, Melissa // Natural Health;May/Jun2001, Vol. 31 Issue 4, p70 

    Presents information about different natural diet supplements used in the management of obesity. Green tea; Ephedra; Chromium.

  • New experimental drug helps obese patients lose weight.  // New York Amsterdam News;02/25/99, Vol. 90 Issue 9, p14 

    Highlights the results of a study conducted at Baylor College of Medicine in Houston, Texas indicating the potency of orlistat to promote weight loss among obese patients. Need for the combination of moderate-calorie diet; Mechanism of the drug's action; Adverse reactions.

  • Focus On Orlistat: A Nonsystemic Inhibitor Of Gastrointestinal Lipase For Weight Reduction In The Management Of Obesity. Chow, Moses S.S.; Reddy, Prabashni // Formulary;Oct98, Vol. 33 Issue 10, p943 

    Discusses orlistat, a nonsystemic inhibitor of gastrointestinal lipase for weight reduction in the management of obesity. Chemistry and pharmacology; Pharmacokinetics; Clinical trials; Guidelines for obesity therapy; Adverse effects; Drug interaction; Dosage. INSET: Formulary Considerations.

  • Safety profile of orlistat: results of a prescription-event monitoring study. Acharya, N. V.; Wilton, L. V.; Shakir, S. A. W. // International Journal of Obesity;Nov2006, Vol. 30 Issue 11, p1645 

    Introduction:Orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK in December 1998. The prescribing information recommends that treatment with orlistat should be discontinued after 12 weeks if the patient has not achieved a specified loss of...

  • Anti-obesity effect of Stellaria media methanolic extract in the murine model of cafeteria diet induced obesity. Chidrawar, Vijay R.; Patel, Krishnakant N.; Bothra, Sunil B.; Shiromwar, Shruti S.; Koli, Akshay R.; Kalyankar, Gajanan G. // International Journal of Nutrition, Pharmacology, Neurological D;May2012, Vol. 2 Issue 2, p121 

    Context: The whole plant of Stellaria media Linn (family Caryophyllaceae) is used by the local people of Dibrugarh district of Assam state, India, as a dietary supplement for the treatment of overweight and is also mentioned in the traditional system of Indian medicine as a remedy for obesity....

  • Profit in Loss. Wellner, Alison Stein // American Demographics;Jul2000, Vol. 22 Issue 7, p46 

    Discusses the development of the XeniCare program offered to patients using the Roche Laboratories' Xenical prescription obesity drug.

  • Press coverage and sales of Xenical in Sweden, 1998—2000. Brounéus, Fredrik; Dahlin, Anna; Beermann, Björn // European Journal of Clinical Pharmacology;Jun2005, Vol. 61 Issue 4, p285 

    Objective: The anti-obesity drug Xenical (orlistat, Roche) was launched on the Swedish market in February 1999. The sales peaked in May 1999 and then declined. The purpose of this study was to investigate the press coverage of Xenical during the period 1998–2000 and, if possible, relate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics